8
项与 GB5005嵌合抗原受体T细胞 相关的临床试验The Safety, Tolerability, Efficacy, and Pharmacokinetic Characteristics of GB5005 Chimeric Antigen Receptor T-cell Injection in Treating Patients With CD19-positive Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
A multi-center, randomized, open-label clinical controlled study of autologous CD19 CAR-T cells alone and its sequential ASCT in the treatment of relapsed and refractory B-cell lymphoma
Safety, tolerability, effectiveness and pharmacokinetics characteristic clinical research of intensive pretreatment combined with GB5005 chimeric antigen receptor T cell injection in the treatment of patients with CD19-positive relapsed / refractory B-cell non-Hodgkin's lymphoma (B-NHL)
100 项与 GB5005嵌合抗原受体T细胞 相关的临床结果
100 项与 GB5005嵌合抗原受体T细胞 相关的转化医学
100 项与 GB5005嵌合抗原受体T细胞 相关的专利(医药)
100 项与 GB5005嵌合抗原受体T细胞 相关的药物交易